APOL1 and Schnyder corneal dystrophy: In addition to emerging immunosuppressing agents, advances in human leukocyte antigen (HLA)/epitope matching, infection prevention, pre-transplant apolipoprotein L1 gene (APOL1), screening standardization of pre-transplant preparation for SCD patients, use of post-transplant SCD disease modifying therapy may impact transplant outcomes of patients with SCD [20,21,22].